Longeveron Inc. (LGVN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LGVN Price/Volume Stats
| Current price | $3.09 | 52-week high | $8.79 |
| Prev. close | $3.10 | 52-week low | $2.50 |
| Day low | $2.95 | Volume | 22,200 |
| Day high | $3.23 | Avg. volume | 117,850 |
| 50-day MA | $2.92 | Dividend yield | N/A |
| 200-day MA | $3.65 | Market Cap | 65.14M |
LGVN Stock Price Chart Interactive Chart >
LGVN POWR Grades
- LGVN scores best on the Sentiment dimension, with a Sentiment rank ahead of 75.51% of US stocks.
- The strongest trend for LGVN is in Growth, which has been heading down over the past 124 days.
- LGVN's current lowest rank is in the Quality metric (where it is better than 5.09% of US stocks).
LGVN Stock Summary
- LONGEVERON INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 12.67% of US listed stocks.
- LONGEVERON INC's stock had its IPO on February 12, 2021, making it an older stock than merely 9.03% of US equities in our set.
- With a price/sales ratio of 61.14, LONGEVERON INC has a higher such ratio than 96.77% of stocks in our set.
- Stocks that are quantitatively similar to LGVN, based on their financial statements, market capitalization, and price volatility, are TDUP, TFFP, ZLAB, RYTM, and VYNE.
- To dig deeper into the stock's financial statements, go to LGVN's page on browse-edgar?action=getcompany&CIK=0001721484.
LGVN Valuation Summary
- In comparison to the median Healthcare stock, LGVN's EV/EBIT ratio is 128.33% lower, now standing at -3.4.
- Over the past 28 months, LGVN's price/sales ratio has gone up 40.6.
Below are key valuation metrics over time for LGVN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LGVN | 2023-05-23 | 62.7 | 4.3 | -3.5 | -3.4 |
| LGVN | 2023-05-22 | 60.9 | 4.2 | -3.4 | -3.3 |
| LGVN | 2023-05-19 | 61.5 | 4.3 | -3.5 | -3.4 |
| LGVN | 2023-05-18 | 59.1 | 4.1 | -3.3 | -3.2 |
| LGVN | 2023-05-17 | 56.7 | 3.9 | -3.2 | -3.1 |
| LGVN | 2023-05-16 | 55.5 | 3.8 | -3.1 | -3.0 |
Longeveron Inc. (LGVN) Company Bio
Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.
Latest LGVN News From Around the Web
Below are the latest news stories about LONGEVERON INC that investors may wish to consider to help them evaluate LGVN as an investment opportunity.
LGVN Stock Earnings: Longeveron Misses EPS, Revenue EstimatesLGVN stock earnings show Longeveron reporting a wider loss than analysts expected and missing revenue estimates. |
LGVN: Announces Results and Progress on a Devastating DiseaseBy Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) announced 1Q 2023 earnings results today and the following are the highlights: • Revenues came in at $0.3 million, as expected, which comes from the company’s Bahamas Registry Trial. • Earnings came in showing a loss of $0.22 per share, roughly inline with expectations. • General and administrative |
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit -- -- First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty in Japan -- -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing regenerative medicines for unme |
Why Is Longeveron (LGVN) Stock Up 30% Today?Longeveron (LGVN) stock is on the move Tuesday after releasing new long-term survival data from HLHS treatment Lomecel-B. |
Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-FreeLongeveron Inc (NASDAQ: LGVN) announced new long-term follow-up data from its ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS). The data showed that 100% of the ten patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery. To date, All ten patients enrolled in the study have been monitored for at least 3.5 years after treatment with Lomecel-BTM. |
LGVN Price Returns
| 1-mo | 6.92% |
| 3-mo | -10.43% |
| 6-mo | -15.57% |
| 1-year | -61.61% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -4.04% |
| 2022 | -73.32% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...